News
In Abrupt Reversal, FDA Yanks Ixchiq Vaccine Over Safety Concern
According to the vaccine's maker, Valneva, the FDA based its decision to suspend the shot on four new serious adverse events that happened outside the U.S., three of which were in people ages 70 to 82 years and the other in a 55-year-old individual.
FDA suspends license for chikungunya vaccine Ixchiq over serious safety concerns
The US Food and Drug Administration (FDA) announced late last week that it has suspended the license for French drugmaker Valneva's chikungunya vaccine, saying that continued administration of the vaccine to the public would pose a danger to health.
Valneva must immediately cease U.S. shipments and sales of Ixchiq, a vaccine for chikungunya virus. The FDA recently lifted a ...
Pharmaceutical Technology on MSN14h
FDA bans Ixchiq in the US, sending Valneva shares plummeting
In a U-turn from a decision two weeks ago, the FDA – citing new safety events – said the vaccine is a "danger to health".
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback